Antony Appleyard serves as the Executive Director of Regulatory Affairs at the Gene Therapy Program. In this role, Antony leads the Regulatory Affairs department which is responsible for regulatory strategy and global health authority interactions. Antony has more than 20 years of experience in research, clinical development, and manufacturing. Previously, Antony was a consultant for nine years at Diamond Pharma Services, where he led a multidisciplinary group providing regulatory support to clients developing cell and gene therapy products.